Resources for pharmacy program members

www.vizientinc.com/PharmacySolutions

Visit our pharmacy webpage for web-based resources and the latest updates

Log into My Dashboard on our website to access

Contact us at PharmacyQuestions@vizientinc.com

SCAN ME

We are here to help

Pharmacy Solutions

Sourcing, clinical and ambulatory support

Analytics

Drug spend and clinical analytics platform

Consulting Services

Operations, ambulatory, 340B, clinical

Aggregation Groups

Pharmacy group purchasing & oncology network

vizient

Pharmacy Market Outlook
Winter 2024

Keeping you at the forefront of drug price projections and market developments

Vizient Pharmacy Solutions
January 31, 2024

vizient®

Housekeeping

- This call is being **recorded**
- Because of the large number of participants, all lines will be kept in **listen-only mode**
- **Questions** will be managed through the Q & A box

vizient

Access & download



Visit the Pharmacy Market Outlook webpage where you can access and download the report as well as other resources

info.vizientinc.com/pharmacy-market-outlook-member-details

Click on the 'Access the report' button (in two places)

Pharmacy program participants

Enjoy access to companion resources and additional information

From this page, you can also access the latest **Budget Impact Projections report** related to the healthcare supply chain.

Gain insight on anticipated price changes over the next 18 months and plan for them now to lessen the impact of 2024 inflation.

Contact us at PharmacyQuestions@vizientinc.com

Additional resources

Drug Budget Forecast

Vizient Savings Actualyzer – Pharmacy

Personalizes the projections with your own spend data

- High level projection analysis and overview
- Detailed report with data filters and dynamic fields
- Editable within portal and exportable

Available to all organizations that participate in the Vizient pharmacy program



Letter to the C-suite

Describes the most consequential issues confronting pharmacy



vizient

Vizient expert contributors

Jared Anderson, PharmD, MS, Clinical Informaticist, Data Applications and Insights

Kevin Baniak, MBA, Director, Analytics and Technology, Pharmacy Solutions

Jered Bauer, PharmD, Senior Vice President, Pharmacy Analytics and Services

Tom Bell, Senior Portfolio Executive, Pharmacy Solutions

Evelyn Bitencourt, Portfolio Executive, Pharmacy Solutions

Justin Cassidy, PhD, Senior Consulting Director, Sg2 Intelligence Team

Carina Dolan, PharmD, MS Pharm, BCOP, AVP of Clinical Oncology, Pharmacoeconomics and Market Insights, Market Intelligence

Emily Diehl, PharmD, BCPPS, Pharmacy Executive, Pharmacy Solutions

Amanda Frick, PharmD, BCPS, Senior Clinical Manager, Market Intelligence

Leah Gannon, PhD, MBA, Director, Contract Services, Pharmacy Sourcing

Annie Halfman, PharmD, PGY2 Resident, Pharmacy Informatics and Supply Chain Leadership

Grace Hawig, PharmD Candidate, Pharmacy Analytics Intern

Jeni Hayes, PharmD, MS Pharm, BCPS, Senior Clinical Manager, Market Intelligence

Shannon Holden, PharmD, BCACP, Senior Clinical Manager, Center for Pharmacy Practice Excellence

Keisha Hyman-Gifth-Turner, Senior Portfolio Executive, Pharmacy Solutions

vizient

Contributors continued

Cory Jones, Associate Principal, Intelligence, Sg2 Intelligence Team

Jimmy Kim, PharmD, MBA-HA, Portfolio Executive, Pharmacy Solutions

Dan Kistner, PharmD, Group Senior Vice President, Blood, Lab and Pharmacy Solutions

Arati Kurani, PharmD, BCPS, Vice President, Advanced Analytics and Informatics

Leslie Larsen, Director, Contract Services, Pharmacy Solutions

Joe Leiman, PharmD, BCPS, MBA, CAPM, Pharmacy Analytics Program Manager

Carolyn Liptak, MBA, RPh, Clinical Pharmacy Director, Center for Pharmacy Practice Excellence

Jimmy Loftin, RPh, Senior Director, Contract Services, Pharmacy Solutions

Jason Londrigan, Senior Portfolio Executive, Pharmacy Solutions

Steven Lucio, PharmD, BCPS, Senior Principal, Pharmacy Solutions

Nikola Markoski, PharmD, MBA, DPLA, Manager, Pharmacy Analytics and Informatics

Madeleine McDowell, MD, FAAP, Senior Principal, Sg2 Intelligence

Nadia Najee, Portfolio Executive, Pharmacy Solutions

Brian Ortega, PharmD, Pharmacy Executive II, Pharmacy Analytics and Services

Pedram Pahlavan, PharmD, AVP, Contract Services, Pharmacy, Acentrus

Priyesh Patel, PharmD, MBA, VP and General Manager, Alluma

Purvi Patel, PharmD, Pharmacy Fellow, Pharmacy Informatics and Supply Chain Leadership

Marquita Pridgeon, MBA, Portfolio Executive, Pharmacy Solutions

Jacob Salmon, Portfolio Executive, Pharmacy Solutions

John Schoen, PharmD, BCPS, Senior Clinical Manager, Center for Pharmacy Practice Excellence

Bryan Shaw, PharmD, Senior Director, Pharmacy Analytics and Residency Program

Sara Stahle, PharmD, MS, BCPS, BCCCP, Director, Data Applications and Insights

Jenna Stern, JD, AVP, Regulatory Affairs and Public Policy

Jade Vitug, PharmD, Senior Portfolio Executive, Pharmacy Solutions

Susan Wescott, RPh, MBA, Sr. Director Managed Care, Mayo Clinic, Alluma

April H. Yoo, PharmD, MPH, BCPS, Director, Pharmacy Solutions

Webinar for financial leaders

Be sure your financial leaders know about this webinar and register now!



Join us for an exclusive perspective designed for financial leaders in your organization

Wednesday, Feb. 28 – 1:00 p.m. CT

Register now

Find more information on vizientinc.com/PharmacySolutions

Contact us at PharmacyQuestions@vizientinc.com

Today’s presenters

Amanda Frick, PharmD, BCPS

Sr Clinical Manager, Market Intelligence

Annie Halfman, PharmD

PGY2 Pharmacy Informatics and Supply Chain Leadership Resident

Jeni Hayes, PharmD, MS, BCPS

Sr Clinical Manager, Market Intelligence

Jenna Stern, JD

AVP, Regulatory Affairs and Public Policy

Methodology and overall numbers

vizient

Price projection methodology overview

Based on Vizient pharmacy program participant data

- Projections 6 to 18 months forward; for price only
- Overall summary, therapeutic class, generic
- Query purchase and price history of member facilities
  - Inclusions: All classes of trade
  - Exclusions: 340B, direct purchases, nondrug purchases
- Determine top 85% of products, based on aggregate spend
- Team makes projections at national drug code (NDC) level
  - Contract products and noncontract products from contract manufacturers: assigned to portfolio executives
  - Other noncontract products: outside data sources

Top
85%
of pharmaceutical purchases

vizient

Overview by the numbers

	July 2023	January 2024
# NDC initial data pull	58,188	57,958
# NDC without exclusions	32,858	32,821
# NDC in top 85%	1,308	1,274
Highest projected Inflation	10% (etoposide, morphine, phenobarbital)	20% (iohexol & sodium phosphate)
Greatest projected deflation	-50% (regadenoson)	-69% (IV acetaminophen)
Number of NDC in both editions	1,166 (92%)	
Number of NDC no longer in top 85%	102	
Number of NDC new to top 85%	113	

Projected drug price inflation
July 1, 2024 through June 30, 2025

This is our highest projected inflation rate since the July 2019 edition (January 2020 – December 2020 prediction window)

Several factors drive the trend of increasing inflation:

- Increase in specialty and ultra-specialty approvals
- Additional indications for previously approved medications, increasing utilization
- Products with higher-than-customary price increases
- Payer restrictions influencing site of care and class of trade implications for pharmacy services

3.80%

Projected overall drug **price** inflation rate

Key therapeutic class highlights

Therapeutic classes	Key products in class	Est. price change
Autoimmune and inflammatory conditions	Humira, Stelara, Entyvio, Skyrizi, Dupixent	3.72%
Biosimilars	Inflectra, Truxima	0.55%
Cardiometabolic diseases	Ozempic, Eliquis, Mounjaro	3.41%
Infectious diseases	Biktarvy, Veklury	4.05%
Neurology	Ocrevus, Botox, Kesimpta, Tysabri	4.60%
Oncology	Keytruda, Opdivo, Darzalex Faspro	3.89%
Pediatrics	Unituxin, Asparlas	3.65%
Plasma critical care	Albumin, Immune globulin intravenous	3.63%
Radiopharmaceuticals	Omnipaque, Visipaque	10.36%

Top 15 drugs ranked by spend

Percent of spend captured by top 15 drugs: **25.77%**

Semaglutide jumps from #10 to #5; Risankizumab-rzaa jumps from #12 to #6

Remdesivir falls out of the top 15 for the first time; Secukinumab new to the list

Rank	Generic name	Brand name	Previous rank
1	Adalimumab	Humira	1
2	Immune globulin, intravenous	Gammagard, Gamunex, Privigen	2
3	Ustekinumab	Stelara	3
4	Pembrolizumab	Keytruda	4
5	Semaglutide	Ozempic, Rybelsus, Wegovy	10
6	Risankizumab-rzaa	Skyrizi	12
7	Dupilumab	Dupixent	9
8	Ocrelizumab	Ocrevus	6
9	Etanercept	Enbrel	8
10	Denosumab	Prolia, Xgeva	5
11	Nivolumab	Opdivo	7
12	Daratumumab-hyaluronidase-fihj	Darzalex Faspro	11
13	Bictegravir / emtricitabine / tenofovir alafenamide fumarate	Biktarvy	14
14	Vedolizumab	Entyvio	15
15	Secukinumab	Cosentyx	--

Top drugs by retrospective price increase

Generic name	Brand name	WAC price change (%)	% of total aggregate spend
Fludarabine	Fludara	653.7%	0.01%
Cefepime in D5W	Maxipime	22.9%	0.07%
Ceftolozane / tazobactam	Zerbaxa	15.3%	0.10%
Denosumab	Prolia, Xgeva	10%	1.16%
Remdesivir	Veklury	9.9%	0.78%
Dinutuximab	Unituxin	9.9%	0.24%
Venetoclax	Venclexta	9.7%	0.25%
Human prothrombin complex concentrate	Kcentra	9.6%	0.43%
Secukinumab	Cosentyx	9.1%	0.81%
Daratumumab Daratumumab-hyaluronidase-fihj	Darzalex Darzalex, Faspro	9.0%	0.10% / 1.08%
Adalimumab	Humira	8.0%	4.46%

Focus for 2024

- Payer cost containment
- Management of high coordination of care medications
- Drug shortages
- Drug pricing
- Advocacy



vizient

Non-acute care highlights

- Biosimilars
- 505(b)(2) approvals
- GLP-1 therapies
- Gene therapies
- Site of care considerations

Biosimilar approvals and launches

Therapeutic Area	Molecule	Reference Product Name Supplier Launch date	Biosimilar Product Name Supplier Launch date
Endocrinology	Insulin glargine	Lantus Sanofi 2000	Rezvoglar ⓘ Eli Lilly Mar. 2023 Semglee ⓘ Viatris Nov. 2021
Immunology	Adalimumab	Humira AbbVie 2002	Abrilada Pfizer Nov. 2023 Amjevita Amgen Jan. 2023 Cyltezo ⓘ Boeheringer Ingelheim July 2023 Hadlima Samsung Bioepis July 2023 Hulio Biocon July 2023 Hyrimoz Sandoz July 2023 Idacio Fresenius Kabi July 2023 Yuflyma Celltrion July 2023 Yusimry Coherus July 2023
Immunology	Etanercept	Enbrel Amgen 2003	Erelzi Sandoz 2029 Eticovo Samsung Bioepis 2029
Immunology	Infliximab	Remicade Janssen 1998	Avsola Amgen July 2020 Inflectra Pfizer Nov. 2016 Renflexis Merck July 2017 Zymfentra ⓑ Celltrion Feb. 2024
Immunology	Tocilizumab	Actemra Genentech 2010	Tofidence Roche 2024
Immunology	Ustekinumab	Stelara Janssen 2009	Wezlana Amgen Jan. 2025
Neurology	Natalizumab	Tysabri Biogen 2004	Tyruko Sandoz 2024
Oncology	Bevacizumab	Avastin Genentech 2004	Alymsys Amneal Oct. 2022 Avzivi Bio-Thera TBD Mvasi Amgen July 2019 Vegzelma Celltrion Mar. 2023 Zirabev Pfizer Dec. 2019
Oncology	Rituximab	Rituxan Genentech 1997	Riabni Amgen Jan. 2021 Ruxience Pfizer Feb. 2020 Truxima Celltrion/Teva Nov. 2019
Oncology	Trastuzumab	Herceptin Genentech 1998	Herzuma Celltrion/Teva Mar. 2020 Kanjinti Amgen July 2019 Ogivri Viatris Dec. 2019 Ontruzant Merck Apr. 2020 Trazimera Pfizer Feb. 2020
Ophthalmology	Ranibizumab	Lucentis Genentech 2006	Byooviz Biogen July 2022 Cimerli ⓘ Coherus Oct. 2022
Supportive Care	Epoetin	Epogen / Procrit Amgen / Janssen 1989	Retacrit Pfizer Nov. 2018
Supportive Care	Filgrastim	Neupogen Amgen 1991	Nivestym Pfizer Oct. 2018 Releuko Amneal Dec. 2022 Zarxio Sandoz Sept. 2015
Supportive Care	Pegfilgrastim	Neulasta * Amgen 2002	Fulphila Viatris June 2018 Fylnetra Amneal May 2023 Nyvepria Pfizer Dec. 2020 Stimufend Fresenius Kabi Feb. 2023 Udenyca Coherus Jan. 2019 Udenyca Onbody Coherus 2024 Ziextenzo Sandoz Dec. 2019

ⓑ Biobetter
ⓘ Interchangeable
Launched
Not launched

*Neulasta Onpro launched 2014

505(b)(2) considerations

- Cost / reimbursement analyses
- Charge master updates
- Formulary evaluations
- Payer coverage
- Prior authorization considerations
- Supply chain / purchaser education

	Approval type	Studies conducted	HCPCS Code	Example
NDA [505(b)(1)]	New (small) molecule	Full safety and efficacy	Reference listed drug	J9056 Inj, bendamustine, 1 mg
ANDA [505(j)]	Generic	Bioequivalence	Generic molecule (share w/other generics & [505(b)(1)]	J9056 Inj, bendamustine, 1 mg
505(b)(2)	Different characteristics	PK, bioavailability	Unique to approval (by manufacturer)	J9036 Inj belrapzo/ bendamustine
351 (a)	Reference biologic	Full efficacy, safety and purity	Biologic molecule	J1745 Infliximab not biosimil 10 mg
351 (k)	Biosimilar	PK, PD, immunogenicity	Unique to each biosimilar	Q5103 Injection, inflectra

505(b)(2) resources

vizient.

Minute Market Insights

Minute Market Insights are intended to highlight changes that may impact drug product selection, drug product utilization or patient care.

Management Strategies

- Consult Drugs @FDA: FDA-Approved Drugs to determine if a medication was approved via the 505(b)(2) pathway.
- Consult the CMS ASP NDC-HCPCS Crosswalk for Medicare Part B Drugs for HCPCS codes by NDC.
- For identified 505(b)(2) NDCs and as new NDCs are added to the formulary, ensure appropriate HCPCS codes are assigned in the charge description master.
- Align key pharmacy and revenue cycle integrity stakeholders for optimal product selection and accurate HCPCS code assignment.
- Consider implementing a policy allowing 505(b)(2) product substitution as clinically appropriate by a pharmacist.

Additional Resources

- 505(b)(2) Frequently Asked Questions
- Applications Covered by 505(b)(2)
- Overview of 505(b)(2) pathway
- Coding for 505(b)(2) drugs
- Vizient has subject matter experts available to answer questions

505(b)(2) Products and Reimbursement

Background

The 505(b)(2) New Drug Application (NDA) approval pathway allows pharmaceutical manufacturers to bring drugs to market more efficiently than traditional pathways. The 505(b)(2) pathway is intended to avoid unnecessary duplication of research for the approval of a clinically significant improvement to a previously approved drug. The manufacturer requesting approval via the 505(b)(2) pathway is allowed to submit data originally collected by another researcher or manufacturer.

Drugs approved via the 505(b)(2) pathway are not generic molecules of the reference or brand name drug and have distinct NDCs. 505(b)(2) drugs are not considered therapeutically equivalent by the FDA but may have similar clinical effects and place in therapy to the listed drug.

What is new?

For Medicare reimbursement, 505(b)(2) products each have unique Healthcare Common Procedure Coding System (HCPCS) codes and payment varies depending on the drug's Average Sales Price (ASP). In January 2023, the Centers for Medicare & Medicaid Services (CMS) made several coding changes:

- Since 505(b)(2) products are approved under separate NDAs and are not rated as therapeutically equivalent by the FDA Orange Book, they are considered single source drugs.
- Because 505(b)(2) products are considered single source drugs, there is a programmatic need for each product to have a unique billing and payment code.
- When products do meet the statutory definition of a generic or multiple source drug and are rated as therapeutically equivalent in the FDA Orange Book, CMS is removing brand names from any existing HCPCS codes as needed (eg, removal of "Velcade" from J9041).

What is the impact?

Billing errors can occur if 505(b)(2) products and formulary decisions are not linked with updates to charge masters and billing processes. Year to date incorrectly coded charges may need to be credited and rebilled.

To learn more, please contact Vizient Center for Pharmacy Practice Excellence, at pharmacyquestions@vizientinc.com.

As the nation's largest member-driven health care performance improvement company, Vizient provides solutions and services that empower health care providers to deliver high-value care by aligning cost, quality and market performance. With analytics, advisory services and a robust sourcing portfolio, we help members improve patient outcomes and lower costs.

Minute Market Insights

505(b)(2) FAQ

505(b)(2) New Drug Application

Frequently Asked Questions

What are the 3 types of new drug applications described under Section 505 of the Federal Food, Drug, and Cosmetic Act?

- An application that contains full reports of investigations of safety and effectiveness (505(b)(1)).
- An application that contains full reports of investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference **(section 505(b)(2).**
- An application that contains information to show that the proposed product is identical in active ingredient, dosage form, strength, route of administration, labeling, quality, performance characteristics, and intended use, among other things, to a previously approved product (section 505(j)).

Why did the Centers for Medicare and Medicaid (CMS) establish new HCPCS Level II codes to separately identify products under the 505(b)(2) New Drug Application (NDA) or the Biologics License Application (BLA) pathways?

In the 3rd quarter of the 2022 HCPCS Coding Cycle, CMS reviewed its approach for establishing HCPCS Level II codes to identify products approved under the 505(b)(2) NDA or the BLA pathways after October 2003. These products are not rated as therapeutically equivalent to their reference listed drug in the Food and Drug Administration's (FDA) Orange Book and are therefore considered single source products.

In order to conform with the general approach used for the assignment of products paid under section 1847A of the Social Security Act (the Act) to HCPCS codes, CMS is made several code changes effective January 1, 2023:

- Due to rating of "not therapeutically equivalent" to the reference listed drugs and consideration as single source products, assignment of manufacturer specific codes to identify products approved under separate 505(b)(2) NDA or BLA pathways.
- Removal of the brand name from existing HPCPS codes when products meet the statutory definition of a multiple source drug to accommodate any associated generic products that are rated as therapeutically equivalent.

How do I know if a medication has been approved through the 505(b)(2) pathway?

There are proprietary subscription-based services that can provide this information, or it can be found on the Drugs @FDA: FDA-Approved Drugs webpage by searching by drug name, active ingredient, or application number.

Go to the Drug Approval Package by clicking on "Review" under Approval Date(s) and History, Letters, Labels Reviews for NDA. The Administrative Document(s) and Correspondence PDF includes the type of exclusivity determination needed (See Part I).

Bendamustine Product Comparison

April 2023

Bendamustine Product Comparison

Table 1. FDA-approved bendamustine products as of April 2023

Supplier	Brand Name	NDA ANDA	Formulation	Vial Type	Strength	Approval Pathway	Orange Book Rating	Infusion Time	Approval Date
Cephalon (Teva)	Treanda	NDA 022249	Solution reconstituted	SDV	25 mg 100 mg	NDA	RLD	30 minutes (CLL) 60 minutes (NHL)	March 2008
ANDA products									
Accord	Bendamustine	ANDA 205574	Solution reconstituted	SDV	25 mg 100 mg	ANDA	AP	30 minutes (CLL) 60 minutes (NHL)	Dec. 2022
Breckenridge	Bendamustine	ANDA 205447	Solution reconstituted	SDV	25 mg 100 mg	ANDA	AP	NR	Feb. 2023
Dr. Reddy's*	Bendamustine	ANDA 205376	Solution reconstituted	SDV	25 mg 100 mg	ANDA	AP	NR	Dec. 2022
505(b)(2) products									
Eagle (Teva)	Bendeka	NDA 208194	Solution	MDV	100 mg/4 mL	505(b)(2)	NR	10 minutes	Dec. 2015
Eagle	Belrapzo	NDA 205580	Solution	MDV	100 mg/4 mL	505(b)(2)	NR	30 minutes (CLL) 60 minutes (NHL)	May 2018
Slayback	Vivimusta	NDA 212209	Solution	MDV	100 mg/4 mL	505(b)(2)	NR	20 minutes	Dec. 2022
Baxter	Bendamustine	NDA 216078	Solution	MDV	100 mg/4 mL	505(b)(2)	NR	30 minutes	Dec. 2022

ANDA = abbreviated new drug application; AP = therapeutically equivalent; IV = intravenous; NR = not reported; PF = preservative free; RLD = reference listed drug; SC = subcutaneous

*Dr. Reddy's gained FDA approval in December 2022 and Breckenridge in February 2023 but neither have launched their product as of 4/23/23.

Bortezomib Product Comparison

Bortezomib Product Comparison

September 2022

...tezomib products

Supplier	Presentation	Formulation	... free	...	...val Pathway	Orange Book Rating	IV administration	SC administration
Takeda (Velcade®)	Solution reconstituted vial	Lyophilized powder	✓	3.5 mg	NDA	RLD	✓	✓
ANDA bortezomib products								
Apotex Athenex Auromedics Baxter Dr. Reddy's Fresenius Kabi Hospira Ingenus Novadoz Sagent Zydus	Solution reconstituted vial	Lyophilized powder	✓	3.5 mg	ANDA	AP	✓	✓
Blue Point Lab Hikma Meitheal	Solution reconstituted vial	Lyophilized powder		3.5 mg	ANDA	AP	✓	✓
505(b)(2) bortezomib products								
Dr. Reddy's 43598-0865-60	Powder for reconstitution vial	Lyophilized powder	✓	3.5 mg	505(b)(2)	NR	✓	
Fresenius Kabi 63323-721-10	Powder for reconstitution vial	Lyophilized powder	✓	3.5 mg	505(b)(2)	NR	✓	
Hospira 00409-1703-01	Powder for reconstitution vial	Lyophilized powder	✓	2.5 mg	505(b)(2)	NR	✓	✓
Hospira 00409-1704-01	Powder for reconstitution vial	Lyophilized powder	✓	1 mg	505(b)(2)	NR	✓	✓

ANDA = abbreviated new drug application; AP = therapeutically equivalent; IV = intravenous; NR = not reported; PF = preservative free; RLD = reference listed drug; SC = subcutaneous

Gene therapy: approvals and pipeline

Dec 2017

Luxturna
Inherited retinal disease

May 2019

Zolgensma
Spinal muscular atrophy

2H 2022

Zynteglo
Beta thalassemia

Skysona
Adrenoleukodystrophy

Hemgenix
Hemophilia B

Adstiladrin
Bladder cancer

2023

Vyjuvek
Epidermolysis bullosa

Elevidys
Muscular dystrophy

Roctavian
Hemophilia A

Lyfgenia
Sickle cell disease (SCD)

Casgevy
Beta-thalassemia, SCD

Pending 2024

Atidarsagene autotemcel
Metachromatic leukodystrophy

Marnetegragene autotemcel (Kresladi)
Primary immunodeficiency

Fidanacogene elaparvovec
Hemophilia B

Prademagene zamikeracel
Epidermolysis bullosa

https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
https://clinical-pipeline.ipdanalytics.com/

Challenges related to gene therapy

Access

- Qualified Treatment Centers (QTCs)

Cost

- $2 million or greater
- Availability of patient assistance programs

Reimbursement

- Single-case agreements
- Outcomes-based agreements

Operations

- Cold chain storage
- Biohazard and safety precautions



Site of care considerations

- Payer mandates
  - White bagging challenges
- Reimbursement challenges
- Patient preference / distance from treatment center

Maximizing different sites of care to meet patient needs



Acute care

Medications that are more than 88% acute care spend

Top acute care medication spend

Rank	Generic name	Brand name
1	Remdesivir	Veklury
2	Sugammadex sodium	Bridion
3	Alteplase	Activase, Cathflo Activase
4	Human prothrombin complex concentrate (PCC)	Kcentra
5	Albumin	AlbuRx, Albutein, Flexbumin
6	Anti-thymocyte globulin (rabbit)	Thymoglobulin
7	Coagulation factor VIIa (recombinant)	NovoSeven
8	Bupivacaine liposomal	Exparel
9	Iohexol	Omnipaque
10	Tenecteplase	TNKase

Source: Vizient pharmacy program participant data, Oct. 2022-Sep. 2023

Proportion of ischemic stroke cases using tenecteplase



Source: Vizient Clinical Data Base/Resource Manager

vizient

Inpatient acuity

CMI trend for inpatient hospital admissions, 2020-2023



Source: Vizient Clinical Data Base. Irving,TX: Vizient, Inc.; 2023.
Q1 2020 – Q2 2023, COVID: Any ICD-10 diagnosis = U071.

Projected timeline and approvals

2024

1H	**Danicopan** Paroxysmal nocturnal hemoglobinuria
1H	**SB15** Biosimilar for Eylea
2024	**Atezolizumab-hyaluronidase (Tecentriq subcutaneous)** NSCLC
2024	**Cosibelimab** Cutaneous squamous cell carcinoma
2024	**Zolbetuximab** Claudin-positive advanced gastric/GEJ cancers
2024	**Formoterol fumarate-mometasone furoate** Generic for Dulera
2024	**Raltegravir potassium** Generic for Isentress
2024	**Ceftaroline fosamil** Generic for Teflaro
2024	**Darunavir ethanolate** Generic for Prezista
2024	**Thalidomide** Generic for Thalomid
2024	**Bromfenac** Generic for Prolensa
2024	**Rotigotine** Generic for Neupro
2024	**Pitavastatin calcium** Generic for Livalo

- New drug approvals
- Regulatory and accreditation events
- Anticipated availability of new generics and biosimilars[a]

Q1

1/1/24	**CMS finalizes exception for biosimilars from OPPS packaging threshold when reference products are separately paid (i.e., CMS will pay separately for certain biosimilars even if cost is below the daily threshold)**
Q1	**Aprocitentan** Treatment-resistant hypertension
Q1	**Cefepime-taniborbactam** Complicated urinary tract infections
Q1	**Donanemab** Alzheimer's disease
Q1	**Givinostat (Duvyzat)** Duchenne muscular dystrophy
Q1	**Marnetegragene autotemcel** Gene therapy - leukocyte adhesion deficiency-I
Q1	**Sotatercept** Pulmonary arterial hypertension
Q1	**Vadadustat (Vafseo)** Anemia due to CKD in adults on dialysis
Q1	**AVT02** Biosimilar for Humira (100mg/mL)

vizient

New and noteworthy approvals
Autoimmune and inflammatory diseases

Drug	Route	MOA	Indication(s)	What's new?
Bimekizumab (Bimzelx)	SUBQ	IL-17 antagonist	Plaque psoriasis	Inhibits both IL-17A and IL-17F
Etrasimod (Velsipity)	Oral	S1PR modulator	UC	2nd in class. No dose titration
Infliximab-dyyb (Zymfentra)	SUBQ	TNF-a inhibitor	Crohn's disease, UC	1st SUBQ formulation of infliximab
Mirikizumab (Omvoh)	IV, SUBQ	IL-23 antagonist	UC	1st IL-23 inhibitor approved
Natalizumab-sztn (Tyruko)	IV	Anti-a4-integrin antibody	Crohn's disease, MS	1st biosimilar for Tysabri
Roflumilast (Zoryve)	Topical	PDE4 Inhibitor	Plaque psoriasis	Expanded to children 6–11 yrs
Secukinumab (Cosentyx)	IV	IL-17 antagonist	PsA, AS, nr-axSpA	New route of administration
Tocilizumab-bavi (Tofidence)	IV	IL-6 receptor antagonist	RA, JIA	1st biosimilar for IV Actemra
Ustekinumab-auub (Wezlana)	SUBQ	IL-12 and IL-23 antagonist	Plaque psoriasis, PsA, Crohn's disease, UC	1st [interchangeable] biosimilar for Stelara; launch anticipated January 2025
Vedolizumab (Entyvio)	SUBQ	Integrin receptor antagonist	UC	1st SUBQ formulation
Zilucoplan (Zilbrysq)	SUBQ	Complement inhibitor	gMG	1st once-daily, self-administered therapy for gMG

vizient

Advocacy in action

Public policy topics

- Biosimilars
- Drug Pricing
- Innovative Payment Models (e.g., CMS Innovation Center)
- Reimbursement
- 340B
- White bagging and other payor-mediated influences
- Drug shortages
- Pandemic-related updates

A busy 2023...

- Developing policy concepts to address drug shortages
- Sharing recommendations related to the 340B remedy repayments
- Supporting policies to increase competition by easing barriers related to biosimilars
- Urging action be taken to address white bagging and other payer-mediated policies
- Opposing site neutral payment policy for certain drug administration services

For more information

- Visit our Public Policy and Government Relations webpage

  vizientinc.com/about-us/public-policy

- Visit our pharmacy member policy webpage

  vizientinc.com/our-solutions/pharmacy-solutions/member-programs/payer-policy-members

Advocacy remains a priority in 2024

Upcoming

- Elections
- Congressional Activity (e.g., funding the government)
- Implementation of the Inflation Reduction Act
- Implementation of the remedy from the 340B Supreme Court decision
- Annual rulemaking

Questions?

Pharmacy program resources

Access & download



Visit the Pharmacy Market Outlook webpage where you can access and download the report as well as other resources

info.vizientinc.com/pharmacy-market-outlook-member-details

Click on the 'Access the report' button (in two places)

Pharmacy program participants

Enjoy access to companion resources and additional information

From this page, you can also access the latest **Budget Impact Projections report** related to the healthcare supply chain.

Gain insight on anticipated price changes over the next 18 months and plan for them now to lessen the impact of 2024 inflation.

Contact us at PharmacyQuestions@vizientinc.com

Additional resources

Drug Budget Forecast

Vizient Savings Actualyzer – Pharmacy

Personalizes the projections with your own spend data

- High level projection analysis and overview
- Detailed report with data filters and dynamic fields
- Editable within portal and exportable

Available to all organizations that participate in the Vizient pharmacy program



Letter to the C-suite

Describes the most consequential issues confronting pharmacy



vizient

Savings Actualyzer for Pharmacy

Live and on-demand training accessible through the member portal

- Vizient Savings Actualyzer – Pharmacy
  – Membership resources
  – Subscription-based resources
- Drug Budget Forecast Report
- Live training registration

Contact PharmacyQuestions@vizientinc.com



vizientinc.com/learning-center/pharmacy-analytics-resources

vizient

Helpful communications

Pharmacy Hot Info	Weekly newsletter with contract price changes, advocacy updates, upcoming webinars
Pharmacy Monitor	Monthly clinical insights
Pharmacy Sourcing Forum call	• Third Wednesday of every month • Contract updates and other important news related to vaccines, drug shortages, product access
Pharmacy Institute	Pharmacy Solutions training and overview for new members or individuals new to their role
VerifiedRx	• Pharmacy podcast with the latest news to support the strategic role of pharmacy • New episodes second Tuesday of each month

Contact us at PharmacyQuestions@vizientinc.com

We are here to help

Pharmacy Solutions

Sourcing, clinical and ambulatory support

Analytics

Drug spend and clinical analytics platform

Consulting Services

Operations, ambulatory, 340B, clinical

Aggregation Groups

Pharmacy purchasing groups & oncology network

Contact us at PharmacyQuestions@vizientinc.com

Let’s work together

vizient®

Contact PharmacyQuestions@vizientinc.com for more information